Phage Abp1 Rescues Human Cells and Mice from Infection by Pan-Drug Resistant Acinetobacter Baumannii

Cellular Physiology and Biochemistry

Volumn 44, Issue 6, 2018, Pages 2337-2345

  Yin, Supeng ^a   Huang, Guangtao ^a   Zhang, Yulong ^a,b   Jiang, Bei ^a   Yang, Zichen ^a   Dong, Zhiwei ^a   You, Bo ^a   Yuan, Zhiqiang ^a   Hu, Fuquan ^a   Zhao, Yan ^a   Peng, Yizhi ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b Number 474 Hospital   (China)

Author keywords

A. baumannii; Cytotoxicity; HeLa cell; Local infection; Phage therapy; Systemic infection; THP 1 cell

Indexed keywords

POLYMYXIN B;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIOPHAGE; CELL PROTECTION; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXICITY; HUMAN; HUMAN CELL; LYSOGENIZATION; MALE; MOUSE; NONHUMAN; PH; PHAGE ABP1; PHAGE THERAPY; PRIORITY JOURNAL; THERMOSTABILITY; ANIMAL; BAGG ALBINO MOUSE; CELL LINE; CELL SURVIVAL; HELA CELL LINE; MULTIDRUG RESISTANCE; PHYSIOLOGY; VIROLOGY;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANIMALS; BACTERIOPHAGES; CELL LINE; CELL SURVIVAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HELA CELLS; HUMANS; MALE; MICE; MICE, INBRED BALB C;

EID: 85038638392     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000486117     Document Type: Article

References (21)

1. Howard A, O'Donoghue M, Feeney A, Sleator RD: Acinetobacter baumannii an emerging opportunistic pathogen. Virulence 2012;3:243-250.
2. Peleg AY, Seifert H, Paterson DL: Acinetobacter baumannii: Emergence of a successful pathogen. Clin Microbiol Rev 2008;21:538-582.
3. Song CT, Hwee J, Song C, Tan BK, Chong SJ: Burns infection profile of singapore: Prevalence of multidrug-resistant acinetobacter baumannii and the role of blood cultures. Burns Trauma 2016;4:13.
4. Fournier PE, Vallenet D, Barbe V, Audic S, Ogata H, Poirel L, Richet H, Robert C, Mangenot S, Abergel C, Nordmann P, Weissenbach J, Raoult D, Claverie JM: Comparative genomics of multidrug resistance in acinetobacter baumannii. PLoS Genet 2006;2:e7.
5. Summers WC: Bacteriophage therapy. Annu Rev Microbiol 2001;55:437-451.
6. Seth AK, Geringer MR, Nguyen KT, Agnew SP, Dumanian Z, Galiano RD, Leung KP, Mustoe TA, Hong SJ: Bacteriophage therapy for staphylococcus aureus biofilm-infected wounds: A new approach to chronic wound care. Plast Reconstr Surg 2013;131:225-234.
7. Harper DR, Morales S: Bacteriophage therapy: Practicability and clinical need meet in the multidrug-resistance era. Future Microbiol 2012;7:797-799.
8. Wu S, Zachary E, Wells K, Loc-Carrillo C: Phage therapy: Future inquiries. Postdoc J 2013;1:24-35.
9. Levin BR, Bull JJ: Population and evolutionary dynamics of phage therapy. Nat Rev Microbiol 2004;2:166- 173.
10. Mattila S, Ruotsalainen P, Jalasvuori M: On-demand isolation of bacteriophages against drug-resistant bacteria for personalized phage therapy. Front Microbiol 2015;6:1271.
11. Huang G, Le S, Peng Y, Zhao Y, Yin S, Zhang L, Yao X, Tan Y, Li M, Hu F: Characterization and genome sequencing of phage abp1, a new phikmv-like virus infecting multidrug-resistant acinetobacter baumannii. Curr Microbiol 2013;66:535-543.
12. Garrison AT, Abouelhassan Y, Kallifidas D, Bai F, Ukhanova M, Mai V, Jin S, Luesch H, Huigens RW, 3rd: Halogenated phenazines that potently eradicate biofilms, mrsa persister cells in non-biofilm cultures, and mycobacterium tuberculosis. Angew Chem Int Ed Engl 2015;54:14819-14823.
13. Thompson MG, Black CC, Pavlicek RL, Honnold CL, Wise MC, Alamneh YA, Moon JK, Kessler JL, Si Y, Williams R, Yildirim S, Kirkup BC, Jr., Green RK, Hall ER, Palys TJ, Zurawski DV: Validation of a novel murine wound model of acinetobacter baumannii infection. Antimicrob Agents Chemother 2014;58:1332-1342.
14. Huang G, Shen X, Gong Y, Dong Z, Zhao X, Shen W, Wang J, Hu F, Peng Y: Antibacterial properties of acinetobacter baumannii phage abp1 endolysin (plyab1). BMC Infect Dis 2014;14:681.
15. Giamarellou H, Antoniadou A, Kanellakopoulou K: Acinetobacter baumannii: A universal threat to public health? Int J Antimicrob Agents 2008;32:106-119.
16. Bradbury J: "My enemy's enemy is my friend." Using phages to fight bacteria. Lancet 2004;363:624-625.
17. Teng T, Liu J, Wei H: Anti-mycobacterial peptides: From human to phage. Cell Physiol Biochem 2015;35:452-466.
18. Sarhan WA, Azzazy HM: Phage approved in food, why not as a therapeutic? Expert Rev Anti Infect Ther 2015;13:91-101.
19. Matsuzaki S, Uchiyama J, Takemura-Uchiyama I, Daibata M: Perspective: The age of the phage. Nature 2014;509:S9.
20. Gong Y, Shen X, Huang G, Zhang C, Luo X, Yin S, Wang J, Hu F, Peng Y, Li M: Epidemiology and resistance features of acinetobacter baumannii isolates from the ward environment and patients in the burn icu of a chinese hospital. J Microbiol 2016;54:551-558.
21. Huang G, Yin S, Gong Y, Zhao X, Zou L, Jiang B, Dong Z, Chen Y, Chen J, Jin S, Yuan Z, Peng Y: Multilocus sequence typing analysis of carbapenem-resistant acinetobacter baumannii in a chinese burns institute. Front Microbiol 2016;7:1717.